We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Celgene buys Pharmion for $2.6bn in cash and stock
20 Nov 2007
Executive Summary
Hematology and oncology immunotherapeutics company Celgene has agreed to purchase Pharmion (cancer treatments) for $2.7bn in cash and stock ($2.6bn net transaction value after subtracting Pharmion's net cash, according to the M&A conference call). Celgene will pay $25 in cash and, based on the current stock prices, $47 in its own stock, for each of Pharmion's outstanding shares; the exact share ratio will be determined when the deal closes. The total $72 per share price is a 45% premium to Pharmion's preannouncement market average.
Deal Industry
Biotechnology
Pharmaceuticals
Pharmaceuticals
Specialty Pharmaceuticals
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Intra-Biotech Deal
Payment Includes Cash
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?